Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740130 | 0.78 | MAPK1 (0.45) | MAPK1GPR119NR1H2 | |
| SCHEMBL31568970 | 0.77 | SCN4A (0.35) | PTPN1MAP4K4MEN1KMT2ASCN4A | |
| SCHEMBL31569367 | 0.76 | SCN4A (0.36) | PTPN1MAP4K4MEN1KMT2AUCHL1 | |
| SCHEMBL31569400 | 0.76 | SCN4A (0.36) | PTPN1MAP4K4MEN1KMT2ASCN4A | |
| SCHEMBL24061284 | 0.75 | SCN4A (0.49) | MAP4K4GPR119MEN1KMT2ASCN4A | |
| SCHEMBL31568968 | 0.75 | SCN4A (0.36) | MAP4K4MEN1KMT2ASCN4A | |
| SCHEMBL22647477 | 0.75 | SCN4A (0.49) | MAP4K4GPR119MEN1KMT2ASCN4A | |
| SCHEMBL30916184 | 0.75 | MAPK1 (0.58) | MAPK1NR1H2 | |
| SCHEMBL741598 | 0.75 | MAPK1 (0.58) | MAPK1NR1H2 | |
| SCHEMBL31569524 | 0.74 | MEN1 (0.37) | MAP4K4GPR119MEN1KMT2ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | MAPK1 1283/4885PTPN1 2093/4885MAP4K4 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.